Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William E Janssen

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Cytotherapy|February 27, 2010
Large-scale Ficoll gradient separations using a commercially available, effectively closed, systemWilliam E Janssen, Albert Ribickas, Laura V Meyer, et al.
Expert Opinion on Biological Therapy|April 28, 2010
INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effectAlberto A Chiappori, Hatem Soliman, William E Janssen, et al.
British Journal of Haematology|June 26, 2003
Mobilized peripheral blood SSCloALDHbr cells have the phenotypic and functional properties of primitive haematopoietic cells and their number correlates with engraftment following autologous transplantationPaul Fallon, Tracy Gentry, Andrew E Balber, et al.
American Journal of Hematology|June 8, 2012
Retrospective comparison of filgrastim plus plerixafor to other regimens for remobilization after primary mobilization failure: clinical and economic outcomesJanelle B Perkins, Jamie F Shapiro, Ryan N Bookout, et al.
Cytotherapy|November 16, 2010
Cell therapy medical tourism: time for actionKurt C Gunter, Arthur L Caplan, Chris Mason, et al.
Journal for Immunotherapy of Cancer|March 22, 2019
A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemiaRosa Nguyen, Huiyun Wu, Stanley Pounds, et al.
Journal for Immunotherapy of Cancer|March 30, 2020
Longitudinal NK cell kinetics and cytotoxicity in children with neuroblastoma enrolled in a clinical phase II trialRosa Nguyen, Natasha Sahr, April Sykes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 24, 2017
A Pilot Trial of Humanized Anti-GD2 Monoclonal Antibody (hu14.18K322A) with Chemotherapy and Natural Killer Cells in Children with Recurrent/Refractory NeuroblastomaSara M Federico, M Beth McCarville, Barry L Shulkin, et al.
Haematologica|June 13, 2012
A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantationJoseph Pidala, Jongphil Kim, Heather Jim, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Cytotherapy|February 27, 2010
Large-scale Ficoll gradient separations using a commercially available, effectively closed, systemWilliam E Janssen, Albert Ribickas, Laura V Meyer, et al.
Expert Opinion on Biological Therapy|April 28, 2010
INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effectAlberto A Chiappori, Hatem Soliman, William E Janssen, et al.
British Journal of Haematology|June 26, 2003
Mobilized peripheral blood SSCloALDHbr cells have the phenotypic and functional properties of primitive haematopoietic cells and their number correlates with engraftment following autologous transplantationPaul Fallon, Tracy Gentry, Andrew E Balber, et al.
American Journal of Hematology|June 8, 2012
Retrospective comparison of filgrastim plus plerixafor to other regimens for remobilization after primary mobilization failure: clinical and economic outcomesJanelle B Perkins, Jamie F Shapiro, Ryan N Bookout, et al.
Cytotherapy|November 16, 2010
Cell therapy medical tourism: time for actionKurt C Gunter, Arthur L Caplan, Chris Mason, et al.
Journal for Immunotherapy of Cancer|March 22, 2019
A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemiaRosa Nguyen, Huiyun Wu, Stanley Pounds, et al.
Journal for Immunotherapy of Cancer|March 30, 2020
Longitudinal NK cell kinetics and cytotoxicity in children with neuroblastoma enrolled in a clinical phase II trialRosa Nguyen, Natasha Sahr, April Sykes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 24, 2017
A Pilot Trial of Humanized Anti-GD2 Monoclonal Antibody (hu14.18K322A) with Chemotherapy and Natural Killer Cells in Children with Recurrent/Refractory NeuroblastomaSara M Federico, M Beth McCarville, Barry L Shulkin, et al.
Haematologica|June 13, 2012
A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantationJoseph Pidala, Jongphil Kim, Heather Jim, et al.
Pageof 1